Patients with a rare inherited eye disorder that causes vision loss and blindness are being treated with a new form of gene therapy. Luxturna (voretigene neparvovec) is a drug from Novartis that carries a steep price—£600,000. However, NHS England has negotiated a lower price with the manufacturer.

The therapy is for patients who have retinal dystrophy; it’s the result of inheriting a faulty copy of the RPE65 gene. The Luturna injection can stop disease progression and may even improve vision.

If you require assistance with vision loss, then please contact SDCB to learn more about our programs.

“Gene therapy to halt rare form of sight loss”